Schrier’s new role places diabetes policy inside the Capitol’s health agenda
Representative Kim Schrier will become the Democratic co-chair of the Congressional Diabetes Caucus when the new Congress convenes in January 2027. The appointment arrives after Representative Diana DeGette lost her re-election earlier this year, ending a long stretch of leadership on diabetes issues from the Colorado Democrat. Representative Gus Bilirakis will remain the Republican co-chair.
Schrier brings an unusual combination of personal and professional experience to the post. She is the only pediatrician serving in Congress and the only member of the House with type 1 diabetes. Her diagnosis came at age 16, placing her among lawmakers who understand diabetes not as an abstraction, but as a lifelong condition shaped by access, affordability, monitoring, and daily treatment burden.
The caucus leadership change matters because diabetes policy in Washington often turns on practical details that directly affect care delivery: whether insulin remains affordable, whether federally supported research continues, and whether specialty care keeps pace with the growing need for prevention and treatment. Those are not separate conversations for endocrinologists and patients; they are the infrastructure of diabetes care.
A physician-lawmaker with lived experience in type 1 diabetes
Schrier’s background gives her a perspective that is both clinical and personal. A pediatrician understands how diabetes affects children and families across developmental stages, from initial diagnosis to long-term self-management. Living with type 1 diabetes adds another layer, one that few lawmakers can bring to the committee room. It means the policy debates over access, emergency coverage, glucose monitoring, and medication pricing are filtered through direct experience with the disease’s daily demands.
That combination may prove especially relevant in a Congress where diabetes advocacy often depends on lawmakers who can translate the disease burden into budget and legislative terms. Endocrinologists know that diabetes management does not stop at prescribing insulin. It depends on whether patients can obtain the drug consistently, whether they can afford the devices and supplies that support glycemic control, and whether federal research dollars continue to sustain progress in prevention and treatment.
Schrier’s role also carries symbolic weight for patients who rarely see a physician with diabetes in the same federal position. Representation alone does not pass legislation, but it can change the tone of hearings, staff briefings, and coalition work. A clinician who has also navigated life with diabetes is likely to approach policy with a tighter link between public debate and bedside reality.
Insulin affordability and the Special Diabetes Program stay at the center
The Endocrine Society has maintained a longstanding partnership with the Congressional Diabetes Caucus, and that relationship is expected to continue under Schrier’s leadership. The society works closely with the co-chairs on issues affecting endocrinologists and the patients they treat, especially insulin affordability and funding for the Special Diabetes Program.
Those priorities reflect two different but connected pressures on care. Insulin affordability determines whether patients can actually follow prescribed treatment plans. Even when a regimen is medically sound, cost barriers can fragment adherence and increase the risk of hyperglycemia, diabetic ketoacidosis, and preventable emergency care. Federal support for the Special Diabetes Program, by contrast, reaches into the research and infrastructure side of the field, helping sustain work that can improve prevention, deepen mechanistic understanding, and refine treatment strategies.
Policy conversations over these issues may sound procedural in Washington, yet their clinical consequences are immediate. A patient who cannot pay for insulin is not facing a theoretical problem. A research program that loses support does not simply slow abstract progress; it delays advances that could affect complication rates, technology use, and long-term disease control.
Leadership continuity after DeGette’s departure
DeGette’s exit from Congress ends a period of established leadership on diabetes policy, and the caucus will now move into a new phase under Schrier and Bilirakis. The transition is straightforward on paper, but it preserves an important bipartisan structure. Bilirakis remains in place on the Republican side, while Schrier takes over for the Democrats, keeping the caucus anchored by lawmakers who have both legislative and policy familiarity with the disease area.
Continuity matters in a field where advocacy cycles can stretch across multiple congressional sessions. Diabetes funding priorities often require repeated attention, not one-time action. Bills can stall. Appropriations can shift. Research protections can be revisited. A caucus with stable leadership can keep those issues visible even when the broader legislative calendar is crowded with competing health, budget, and election-year pressures.
Schrier’s appointment also arrives at a moment when diabetes care continues to intersect with broader federal questions about chronic disease spending, workforce access, and public research support. Pediatricians, endocrinologists, primary care clinicians, and patients all face the same practical challenge: sustaining a care model that is medically sound and financially reachable. Federal advocacy does not replace clinical practice, but it shapes the conditions under which that practice can succeed.
What this leadership change could mean for endocrine advocacy
For endocrinology, the caucus shift offers an opportunity to keep diabetes policy grounded in the realities of treatment. The Endocrine Society’s statement made clear that it views Schrier as a partner in advancing legislation aimed at better prevention, increased research, and better treatment of diabetes. Those goals align closely with the field’s daily clinical priorities, where glucose control, complication prevention, and patient access all depend on policy choices made far from the exam room.
A physician with type 1 diabetes leading the Democratic side of the caucus may sharpen the case for patient-centered legislation. Insulin pricing, research support, and coverage policy can all be framed not only as administrative issues, but as determinants of whether patients receive consistent, lifesaving care. In a disease where small disruptions can carry large metabolic consequences, that distinction has direct clinical weight.
The coming Congress will determine how much influence that perspective has in practice. For now, the caucus leadership change places an endocrinology-trained clinician with lived experience at the center of diabetes advocacy, with insulin access and federal research support already defined as early priorities.